Healthy volunteer study explores how KarXT behaves in fast and slow metabolizers

NCT ID NCT07204418

First seen Oct 31, 2025 · Last updated May 14, 2026 · Updated 26 times

Summary

This study looks at how the drug KarXT is broken down in healthy adults who have different types of a liver enzyme called CYP2D6. About 56 participants will be grouped by their metabolism speed (normal, intermediate, poor, or ultrarapid). The goal is to measure drug levels and safety, helping doctors understand how to dose KarXT based on a person's genetic makeup.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Anaheim Clinical Trials

    RECRUITING

    Anaheim, California, 92801, United States

    Contact Phone: •••-•••-••••

  • ICON - Lenexa

    RECRUITING

    Lenexa, Kansas, 66219-9746, United States

    Contact Phone: •••-•••-••••

  • ICON Development Solutions

    RECRUITING

    San Antonio, Texas, 78209, United States

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.